Paul Riley elected as Fellow of the Royal Society
REACT Co-director Professor Paul Riley joins outstanding researchers from across the world who have this year been elected to the Fellowship of the Royal Society, the UK’s national academy of sciences. Paul is recognised for his contribution to …
Molecular and functional MRI enables detection of cardiac fibrosis and evaluation of treatment response after chordin-like 1 gene therapy in myocardial infarction
Konstantina Amoiradaki …
Zeb2os Hinders Cardiac Healing by Suppressing ZEB2 Reactivation and Cardiomyocyte Dedifferentiation
Rocco Caliandro …
Career development
As the field of gene therapies to stimulate cardiac repair is emerging and rapidly evolving, specialist training opportunities remain limited. Through REACT, we address this gap by convening leading experts from the UK and internationally to deliver a …
Professor Paul Riley
Paul is BHF Professor of Regenerative Medicine and Director of the Institute of Developmental and Regenerative Medicine at the University of Oxford. His research interests span cardiovascular developmental biology and modelling congenital heart disease, …
Responsible research
We expect all research conducted across the MRC/BHF CoRE in Advanced Cardiac Therapies to be rigorous, trustworthy and open. Many aspects of our work will be shared openly, usually disseminated through this website, including key research outputs such as …
Trained Immunity and Cardiovascular Risk: An Immunological Perspective
Katherine A. Boden …
Studentships
We are not currently advertising any PhD studentships. …
Determining mechanisms of cardiomyocyte proliferation-driven vascularisation
Although survival rates after myocardial infarction (MI) have improved, permanent loss of heart muscle cells often results in progressive heart failure. Restoring blood supply through angiogenesis (the growth of new blood vessels) could protect vulnerable …